Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens (Q40415200)

20 September 2017

Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens (English)

1 reference

20 September 2017

1 reference

Giulietta Maruggi

1

1 reference

20 September 2017

Emiliano Chiarot

2

1 reference

20 September 2017

Cinzia Giovani

3

1 reference

20 September 2017

Scilla Buccato

4

1 reference

20 September 2017

Stefano Bonacci

5

1 reference

20 September 2017

Elisabetta Frigimelica

6

1 reference

20 September 2017

Immaculada Margarit

7

1 reference

20 September 2017

Andrew Geall

8

1 reference

20 September 2017

Giuliano Bensi

9

1 reference

20 September 2017

Domenico Maione

10

1 reference

20 September 2017

language of work or name

English

0 references

publication date

7 December 2016

1 reference

20 September 2017

1 reference

20 September 2017

35

1 reference

20 September 2017

361-368

1 reference

20 September 2017

2

1 reference

RNA: the new revolution in nucleic acid vaccines

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Intradermal electroporation of naked replicon RNA elicits strong immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Immunologic basis of vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Vaccine design for CD8 T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

DNA vaccines: an historical perspective and view to the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Clinical applications of DNA vaccines: current progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

DNA vaccines: ready for prime time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Messenger RNA-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Nonviral delivery of self-amplifying RNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Synthetic DNA delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Adjuvants for human vaccines--current status, problems and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Identification of a universal Group B streptococcus vaccine by multiple genome screen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

N-linked protein glycosylation in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Assembly and role of pili in group B streptococci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Pilus Backbone Contributes to Group BStreptococcusParacellular Translocation through Epithelial Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

A maternal vaccine against group B Streptococcus: past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

How bacterial carbohydrates influence the adaptive immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Adaptive Immunity against Streptococcus pyogenes in Adults Involves Increased IFN-γ and IgG3 Responses Compared with Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

The Fall of a Dogma? Unexpected High T-Cell Memory Response to Staphylococcus aureus in Humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Vaccines 'on demand': science fiction or a future reality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.040

10.1016/J.VACCINE.2016.11.040

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference